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Abstract
Background
Severe anaemia is a major cause of morbidity and mortality in HIV-infected adults living in
resource-limited countries. Comprehensive data on the aetiology are lacking but are needed
to improve outcomes.
Methods
HIV-infected adults with severe (haemoglobin�70g/l) or very severe anaemia (haemoglo-
bin� 50 g/l) were recruited at Queen Elizabeth Central Hospital, Blantyre, Malawi. Fifteen
potential causes and associations with anaemia severity and mortality were explored.
Results
199 patients were enrolled: 42.2% had very severe anaemia and 45.7% were on ART. More
than two potential causes for anaemia were present in 94% of the patients including iron
deficiency (55.3%), underweight (BMI<20: 49.7%), TB infection (41.2%) and unsuppressed
HIV infection (viral load >1000 copies/ml) (73.9%). EBV/CMV co-infection (16.5%) was
associated with very severe anaemia (OR 2.8 95% CI 1.1–6.9). Overall mortality was high
(53%; 100/199) with a median time to death of 17.5 days (IQR 6–55) days. Death was asso-
ciated with folate deficiency (HR 2.2; 95% CI 1.2–3.8) and end stage renal disease (HR 3.2;
95% CI 1.6–6.2).
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Conclusion
Mortality among severely anaemic HIV-infected adults is strikingly high. Clinicians should
be aware of the urgent need for a multifactorial approach including starting or optimising HIV
treatment, considering TB treatment, nutritional support and optimising renal management.
Introduction
Anaemia is recognized as the most common haematological complication of Human Immu-
nodeficiency Virus (HIV) infection worldwide [1,2] The World Health Organization (WHO)
defines anaemia as a haemoglobin level below 110–120 g/l. In sub-Saharan Africa, 60% of
HIV-infected adults are anaemic and 22% are severely anaemic [3,4]. Anaemia is associated
with an increased one-year mortality in HIV infection of 8%, which rises to 55% in those with
severe anaemia [5,6]. Anaemia treatment may even improve survival [7]
To prevent and treat severe anaemia in HIV-infected patients, a comprehensive under-
standing of the aetiology and pathophysiology is essential. Severe anaemia in HIV infection
has been associated with micronutrient deficiencies, infections (viral, bacterial and parasitic)
and inflammation, medication induced (zidovudine and cotrimoxazole) and neoplastic dis-
eases [8–12]. Only a few studies have comprehensively studied the multifactorial aetiology and
pathophysiology of HIV-associated severe anaemia in sub-Saharan Africa despite the high bur-
den of HIV infection in this region [2]. Commonly, studies only report on the association
between HIV infection and a single cause of severe anaemia, for example iron deficiency, with-
out considering the multiple causes of severe anaemia that may impact on an HIV-infected
patient [13,14]. As a consequence, evidence to inform preventive or treatment guidelines for
severe anaemia in HIV-infected patients in sub-Saharan Africa is scarce. In practice, severe
anaemia management in HIV-infected patients is often still based on the same strategies used
for non-HIV infected patients, including iron supplementation, malaria treatment and de-
worming [2,15]. These strategies may be ineffective as the causes of HIV-associated severe
anaemia may be different, and even harmful, since iron supplementation may exacerbate
infections and potentially cause deterioration of the patient’s condition [16,17].
Better knowledge about the aetiology of severe anaemia is essential in order to develop evi-
dence-based protocols and ultimately improve outcomes for HIV-infected adults with severe
anaemia in sub-Saharan Africa. To address this knowledge gap, we performed a comprehen-
sive observational cohort study to explore the prevalence of potential aetiologies of HIV-asso-
ciated severe anaemia in Malawian in-patients, and studied associations between these and the
severity of the anaemia and patient outcomes.
Methods
An observational cohort study of HIV-infected patients with severe anaemia (haemoglobin
�70 g/l) admitted to the Queen Elizabeth Central Hospital (QECH), Blantyre, Malawi between
February 2010 and March 2011 was performed. All HIV-infected patients above 18 years of
age with severe anaemia admitted to the general medical ward were approached and enrolled
in the study if they provided informed consent. A case record form including a detailed medi-
cal history and physical examination was completed for each enrolled patient. On admission a
venous blood sample was collected and a chest X-ray was performed. The patients were man-
aged according to the hospital protocols, which included a blood transfusion if required,
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treatment of correctable conditions including anti-malarial medication and antibiotics. Anti-
retroviral treatment (ART) was provided according to the national Malawi guidelines, which
stipulated that ART should only be initiated by specialist outpatient clinicians, so patients were
not started on ART on in-patient wards. At the time of the study first line ART was a combina-
tion of stavudine, lamivudine and nevirapine and second line treatment was a combination of
zidovudine, lamivudine, tenofovir and lopinavir/ritonavir [18]. ART was only prescribed for
WHO stage 3 and 4 disease, or WHO stage 1 and 2 disease with CD4 count < 350 x 109/l
[18,19]. Cotrimoxazole was prescribed routinely to all HIV-infected patients on ART as Pneu-
mocystis Jirovecii prophylaxis. For this study patients were followed up in a dedicated ART
clinic after discharge. Follow-up was done for a maximum of 365 days after enrolment, or
when they attended the ART clinic for routine appointments or, if they failed to attend, by a
home visit from a study nurse.
Laboratory assays
All samples were analysed within 24 hours of collection or stored at -80˚C for further analysis.
On enrolment haemoglobin concentrations were measured on the ward using the HemoCue
B-Haemoglobin analyser (HemoCue, A¨ngelholm, Sweden) to screen for eligibility. For
patients enrolled in the study, the haemoglobin and red cell indices (MCV, MCH and MCHC)
were determined using an automated analyser (Beckman Coulter, Durban, South Africa).
CD4-cell counts were assessed using BD FACS Count (BD Biosciences, San Jose, CA, USA).
Transferrin, iron, ferritin, folate and vitamin B12 were analysed on Modular P800 and Monu-
lar Analytic E170 systems (Roche Diagnostics, Switzerland). Soluble transferrin receptor
(sTfR) levels were measured using ELISA (Ramco Laboratories, TX, USA). Serum creatinine
was analysed using a Beckman Coulter CX5 (ADVIA 2400 Siemens Healthcare Diagnostics).
Renal function was measured by estimating glomerular filtration rate (eGFR) using simplified
Modification of Diet in Renal Disease (MDRD)-Study formula and the GFR was classified by
Chronic Kidney Disease classification [20–22]. For all tests the manufacturers’ reference
ranges were used; internationally accepted cut-offs were used to define deficiencies [23]. Thick
blood films were prepared and stained for malaria microscopy. Malaria was defined as the
presence of Plasmodium falciparum asexual parasites in the blood films. HIV infection was
confirmed using two point-of-care antibody tests (Unigold1 and Determine1). For blood cul-
tures a venous blood sample was inoculated into BACTEC Myco/F-Lytic culture vials and
incubated in a BACTEC 9050 automated culture system (Becton Dickinson) for 56 days. Sub-
culturing blood and sputum, susceptibility testing and isolate identification were performed by
standard techniques [23,24]. Likely contaminants were recorded as absence of pathogens. Spu-
tum cultures were examined for mycobacteria using Ziehl–Nielsen staining. Whole-blood iso-
lates were assessed for Epstein–Barr virus and cytomegalovirus infection by semi-quantitative
PCR and for parvovirus B19 by real-time PCR [25]. All chest X-rays were reviewed by a radiol-
ogist for signs of pulmonary tuberculosis (TB). When TB was suspected, standardized treat-
ment was started according to the local protocols.
Bone marrow
If the patient’s clinical condition allowed and they provided consent, a bone marrow aspirate
and trephine biopsy were performed. All bone marrow samples were taken from the posterior
iliac crest. Samples of the aspirates were spread onto slides and trephine biopsies were fixed,
decalcified and embedded in paraffin wax [26, 27]. Bone marrow samples were sent to the
Haematopathology Referral Centre at the Royal Liverpool University Hospital, Liverpool UK,
for analysis. Sections of the trephine blocks were stained with haematoxylin and eosin, and
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Giemsa, with Perls stain for iron, and for reticulin [26]. Bone marrow analysis was performed
by pathologists who were unaware of the patients’ data. All slides were examined for using a
predefined format and diagnoses were allocated to the categories lymphoproliferative disease,
myeloproliferative disease, myelodysplastic syndrome (MDS), TB and ‘other’ [28–30]. The
need for additional histochemical (e.g. Ziehl-Neelsen) or immunohistological (e.g. CD3,
CD20) staining was determined according to the local protocol in Liverpool depending on the
preliminary morphological findings.
Definitions for potential factors involved in the aetiology of severe anaemia
A total of 15 potential factors involved in the aetiology of severe anaemia were investigated.
Factors were based on two previous studies performed in Malawi and a systemic review on
this topic [31–33].and comprised (with definitions) 1) Unsuppressed HIV-infection; viral load
�1000 copies/ml. 2) TB: presence of one or more of the following: a) positive sputum culture,
b) chest X-ray with signs of pulmonary TB and/or c) on going TB treatment at time of enrol-
ment d) clinical diagnosis by local doctor including unknown generalized lymphadenopathy
and/or night sweats of> 30 days and of unknown origin e) caseating granulomata in the bone
marrow trephine. 3) Malaria: presence of malaria parasites in a thick blood film. 4) parvovirus
B19: viral load of>1000 copies/ml. 5) Cytomegalovirus (CMV); viral load of>100 copies/ml.
6) Epstein-Barr virus (EBV); viral load of>100 copies/ml. 7) Bacteraemia; a blood culture
growing a potential pathogen. 8) Underweight (BMI�18.5). 9) Serum folate deficiency (�3
ng/l). 10) Vitamin B12 deficiency (�180 pg/ml). 11). Iron deficiency; In a sub study (Huibers
et al PLOS One 2019) we evaluated bone marrow (BM) iron deficiency using several conven-
tional blood markers; MCV (fl), MCH (pg/cells), Fe (umol/l), ferritin (ug/dl), TFr1 receptor
(nmol/l), TrF index (stFR/Log ferritin). All markers showed suboptimal correlations (i.e.
AUCROC < 0.6) with BM iron deficiency, though MCV performed best (AUCROC 0.545).
MCV was therefore used to identified iron deficiency as it was the best (though suboptimal)
conventional marker in our setting. It was also available for patients beyond the subgroup
(n = 76) who had a bone marrow result and it is available in most African settings [3, 22, 33].
Since an MCV <83fL is commonly used in other studies and guidelines [3, 22, 33] and it was
the best predictor of BM iron deficiency in our setting, we used it as the marker for iron defi-
ciency in this analysis. As the AUC-ROC was suboptimal we chose to call it MCV�83fL rather
than iron deficiency. 12) Zidovudine usage. 13) Cotrimoxazole usage. 14) Bone marrow disor-
ders; lymphoproliferative disease, myeloproliferative disease or MDS. 15) Renal impairment: a
GFR which either indicated impaired (GFR 15–59 ml/min/1.73 m2) or End Stage (GFR�15
ml/min/1.73 m2) Renal Disease [22,35]].
Statistics
The study was primarily designed to give a complete overview of the potential factors associ-
ated with severe anaemia, including lymphomas, in severely anaemic African patients infected
with HIV. The selected sample size of 200 would be able to detect an estimated prevalence of
5% or 10% with confidence intervals of 2.4% - 9% and 6–15% respectively. Baseline character-
istics and prevalence of potential risk factors are presented as proportions or medians with
IQR. Logistic regression was performed to model the association between anaemia and poten-
tial factors associated with anaemia. Results are expressed as OR with 95% CI and p-values.
Variables associated with the outcome variables (P� 0.10) in the univariate analysis were
included in the multivariate model in a stepwise approach. Kaplan Meier survival curves were
used to assess cumulative mortality. Significant differences were investigated with a Log Rank
test. Uni- and multivariate analyses were done using logistic regression and Cox regression to
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describe predictors of overall mortality. A sub- analysis was performed for mortality within 60
days. A sub analysis was performed to evaluate the distribution of co-existing factors between
mortality within and after 60 days. Group comparisons for categorical data were performed
using the χ2 test or Fisher’s exact test, and for continuous data using the t-test or the Wilcoxon
rank-sum test. P values of< 0.05 were regarded as statistically significant. All reported P values
were two-sided. The data were analysed using Stata (version 12) (STATA Corp. LP, Texas, TX,
USA).
Ethics
The Research Ethics Committee of the College of Medicine, University of Malawi
(P.09.09.824) and the Research Ethics Committee of Liverpool School of Tropical Medicine
(research protocol 09.64) approved the study. The purpose of the study was explained to the
patients in the local language (Chichewa) and written informed consent was obtained before
inclusion in the study.
Results
In total, 199 patients were included in the study: 64.8% were female. The median age was 32
years (IQR 27–61 years). The median haemoglobin was 53 g/l (IQR 4.2–6.3) and 84 (42%)
patients had very severe anaemia (Hb� 50 g/l). A total of 91 (45.7%) patients were on ART at
enrolment including 79.1% on first line ART. During the study period, an additional 41 (21%)
patients started on ART treatment. 67.1% of the patients were immune suppressed with a CD4
count� 200 cells/mm. Baseline characteristics of the patients are shown in Table 1.
The prevalence of factors and their association with severe anaemia is shown in Table 2. An
unsuppressed HIV-infection occurred in 73.9% patients. TB was the second most common
infection occurring in 82 (41.2%) of the patients. In 19 (23%) of these patients TB was diag-
nosed on their chest X-ray. Granulomata were seen in the bone marrow trephine in 15 (18%)
of all the 82 patients that had a diagnosis of TB. 11 (13%) patients were on TB treatment at
enrolment. 69/170 (40.5%) patients had evidence of current EBV infection and 57/170 (33.5%)
had evidence of current CMV infection. Co-infection with CMV and EBV was found in 28/
170 (16.5%) of the patients. Bacteraemia was diagnosed on a positive blood culture in 26
(13.1%); the most common pathogens were E. Coli (12 patients; 42.9%) and non-Typhoid Sal-
monella (5 patients; 19.9%). 74/148 (49.7%) patients were underweight and MCV� 83 fl
occurred in 61/180 (33.9%) of the patients. Bone marrow sampling was performed in 73
patients. Of these, 28 (38.4%) had morphological abnormalities with MDS being the most
common abnormality (20 patients; 27.4%) (Table 2). Renal impairment was diagnosed in 36/
185 patients (19.5%) and 12 of these patients (33%) had end stage renal disease. Overall,
patients had a mean of 3 (range 1–8) co-existing aetiologies of severe anaemia (Fig 1). The
overlap of factors is visually displayed in supplemental S1 Fig.
Comparing the different risk factors between very severe anaemia (Hb < 50g/L) and severe
anaemia, EBV/CMV co-infection (OR 2.8 95% CI 1.1–6.9) was the only factor associated with
very severe anaemia (Table 2).
During the one-year follow-up period, 101 study patients (50.8%) died. The median time to
death was 17.5 days (IQR 6–55) and 81 (80.2%) of these deaths occurred within 60 days of
admission (Fig 2). The factors associated with mortality within 60 days and those associated
with overall mortality in HIV-infected adults in Malawi are provided in S1 Table. Folate defi-
ciency and end stage renal disease were associated with overall mortality with Hazard Ratio 2.0
(95% CI 1.2–3.6) and Hazard Ratio 3.0 (95% CI 1.5–5.9) respectively (Fig 3). Only end stage
renal disease (Hazard Ratio 2.7 95% CI 1.2–6.2) was associated with mortality within 60 days
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(S2 Table). Neither very severe anaemia (haemoglobin�50 g/l) nor the haemoglobin levels
were associated with mortality in the study patients (Hazard Ratio 0.9, 95%CI 0.6–1.4 and
Hazard Ratio 1.01, 95% CI 0.9–1.2 respectively).
Discussion
In this study we described the prevalence of several potential aetiologies for severe and very
severe anaemia in HIV-infected Malawian adults. Patients had a mean of three co-existing
aetiologies potentially contributing to their anaemia, the most common one being unsup-
pressed HIV infection. Mortality in the study patients was extremely high, as 51% of the
patients died within one year and most died within 60 days of admission. Severe anaemia in
HIV-infected patients in a resource limited setting, such as Malawi, is therefore a multi-causal
critical condition associated with high mortality.
Anaemia in HIV-infected patients is an independent predictor of mortality with deaths
increasing as haemoglobin concentrations decrease [6, 35]. However HIV pathogenesis is
complex and although anaemia may contribute to morbidity and mortality, the data suggest
that the aetiology is multi-causal. Previous studies have reported an estimated one-year mor-
tality of 30–55% in severely anaemic, compared to 3.7% in non-anaemic, HIV-infected
patients in resource limited settings [5, 6]. Our study results are consistent with these out-
comes. The seriousness of severe anaemia and its complexity in HIV-infected patients needs to
be better recognized. Whether severe anaemia is the direct cause of the mortality or indirectly
Table 1. Baseline characteristics of HIV-infected patients with severe anaemia at enrolment into study.
Overall
Age, years (median IQR) 32 (IQR 27–61)
Sex (female) 129/199 (64.8%)
Haematology
Haemoglobin (Hb) (median, IQR) g/l 53 (IQR 42–63)
Severe anaemia (Hb 51–70 g/l)
Very severe anaemia (Hb� 50g/l)
115/199 (57.8%)
84/199 (42.2%)
Pancytopenia1 42 /184 (21.2%)
Mortality
Overall mortality (365 days)
Early mortality (60 days)
Days until death (median, IQR)
101/199 (50.8%)
81/101 (80.2%)
17.5 days (6–55)
HIV-disease and treatment
CD4 (median, IQR)
CD4�200 cells/mm3
175 (IQR 55–825)
104/155 (67.1%)
Viral load�1000 copies/ml 136/184 (73.9%)
ART at enrolment
First-line ART
Second-line ART
Non-specified ART
91/199 (45.7%)
72/199 (36.2%)
11/199 (5.5%)
8/199 (4%)
Blood transfusions and supplemental treatment
Blood transfusion at enrolment 47/199 (23.6%)
Folate supplementation at enrolment 57/199 (28.6%)
Iron supplementation at enrolment 81/199 (40.7%)
Vitamin B12 supplementation at enrolment 0/199 (-)
1 Pancytopenia is defined as thrombocytopenia (�150 x 109/l) and leucopenia (�4 x 109/l) and severe anaemia
(Hb� 70 g/l) [22]. Abbreviations: Hb: Haemoglobin, ART: antiretroviral therapy.
https://doi.org/10.1371/journal.pone.0218695.t001
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responsible through other contributing factors, severe anaemia should be recognized by clini-
cians as a sign of critical HIV disease and should therefore should be classified as a stage 4 con-
dition instead of its current stage 3 classification [36, 37].
Unsuppressed HIV virus was present in 79% of the patients in our study population. HIV
may cause anaemia directly through an inhibitory effect of the HIV-virus on the erythropoie-
tin progenitor cells in the bone marrow, or indirectly through opportunistic infections and/or
inflammation causing anaemia [38]. A large cross-sectional study in Tanzania showed that the
risk of developing severe anaemia in HIV-infected patients was increased two- to three-fold
among patients with advanced HIV disease [3]. Our findings, and those of previous studies,
Table 2. Distribution and multivariate analysis of co-existing factors associated with severe (Hb� 70 g/l- Hb> 50 g/l) and very severe anaemia (Hb� 50 g/l) in HIV-
infected adults in Malawi.
Overall N = 199
(100%)
Severe anaemia
N = 115/199
(57.8%)
Very severe
anaemia
N = 84/199 (42.2%)
Univariate Multivariate
Odds 95% -CI P-value Odds 95% -CI P-
value
Sex (female) 129 (64.8%) 74/115 (65.2%) 55/84 (65.4%) 1.1 0.6–1.9 0.869 - - -
HIV
CD4�200 cells/mm3 104/155 (67.1%) 62/87 (71.3%) 42/68 (61.8%) 1.04 0.6–1.8 0.889 - - -
Viral load�1000 copies/ml 136/184 (73.9%) 81/104 (77.9%) 55/80 (68.8%) 0.6 0.3–1.2 0.163 - - -
On ART at enrolment 91/199 (42.7%) 52/115 (40.9%) 39/84 (45.2%) 1.1 0.6–1.8 0.865 - - -
Infection
Malaria 6/167 (1%) 3/100 (3.0%) 3/67 (4.5%) 1.5 0.3–7.8 0.617 - - -
Tuberculosis 82/199 (41.2%) 53/115 (46.0%) 29/84 (34.5%) 0.7 0.6–0.99 0.043 0.6 0.1–2.8 0.507
Bacteraemia1 26/199 (13.1%) 17/115 (61.7%) 9/82 (11.0%) 0.7 0.3–1.6 0.402 - - -
Parvovirus B19 7/170 (4.2%) 5/99 (5.0%) 2/71 (2.8%) 0.5 0.1–2.9 0.476 -
Cytomegalovirus (CMV) 57/170 (33.5%) 28/99 (28.3%) 29/71 (40.8%) 1.8 0.9–3.3 0.088 - -
Epstein-Barr virus (EBV) 69/170 (40.6%) 40/99 (40.4%) 29/71 (40.8%) 1.0 0.6–1.9 0.954 - - -
EBV/CMV co-infection 28/170 (16.5%) 12/99 (12.1%) 16/71 (22.5%) 2.1 0.9–4.5 0.075 2.8 1.2–7.0 0.024
Malnutrition
Underweight 74/148 (49.7%) 40/81 (49.3%) 34/68 (50.0%) 1.0 0.5–2.0 0.940 - - -
Vitamin B12 deficiency 2/194 (1.0%) 1/113 (0.8%) 1/81 (1.2%) 1.4 0.09–
22.7
0.813 - - -
MCV� 83 fl2 61/180 (33.9%) 38/104 (36.5%) 23/76 (30.3%) 0.8 0.40–
1.42
0.380 - - -
Folate deficiency 23/194 (11.9%) 13/113 (11.5%) 10/84 (11.9%) 1.1 0.5–2.6 0.858 - - -
Medication
Cotrimoxazole 163/199 (81.9%) 99/115 (81.6%) 64/84 (76.2%) 0.5 0.3–2.3 0.076 0.5 0.2–1.2 0.120
Zidovudine 13/199 (6.5%) 5/50 (10.0%) 8/40 (20.0%) 2.3 0.7–7.5 0.187 - - -
Renal function
Impaired (GFR 15–60) 24/185 (13.0%) 12/105 (11.4%) 12/80 (15.0%) 1.5 0.6–3.6 0.339
End stage (GFR�15) 12/185 (6.5%) 3/105 (2.9%) 9/80 (11.3%) 4.6 1.2–17.6 0.027 4.0 0.9–16.8 0.061
Bone marrow
Bone marrow disease 28/71 (39.4%) 19/42 (45.2%) 9/29 (31.0%) 0.5 0.2–1.5 0.231 - -
Aetiology
Co-existing aetiologies per patient (mean,
SD)
3.3 (1.3) 3.3 (1.2) 3.2 (1.4) 0.8 0.4–1.8 0.605 - - -
1 A total of 28-blood cultures were positive, the most common organisms were E. coli (42.9%; 12/28) and non-Typhoid Salmonella (17.9%; 5/28). 2 Iron deficiency was
defined by MCV� 83 fl. Explanatory variables associated with the outcome variables (P > 0.10) in the univariable analysis were excluded in the multivariable model in a
stepwise approach (-). Abbreviation: GFR; Glomerular filtration rate.
https://doi.org/10.1371/journal.pone.0218695.t002
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indicate that controlling HIV infection by starting or switching ART treatment should be
prioritised as the most important and urgent step in treatment protocols for severely anaemic
HIV-infected patients. After our study had been completed guidelines for initiating ART
changed. At the time of the study the trigger for starting ART was based on a patient’s CD4
count, whereas it is currently recommended that ART should be started early in the course of
HIV disease [18, 37]. It will be important for the impact of this policy change on HIV-related
anaemia, and its consequences, to be evaluated. Irrespective of the policy change for initiating
ART, the findings of our study remain very relevant because many HIV-infected patients in
resource-limited settings present late in the course of their disease or are unable to access reli-
able supplies of ART. Consequently this patient population is likely to experience high levels of
life-threatening anaemia since it is closely associated with severe HIV disease and may be exac-
erbated by the effect of medication such as zidovidine and cotrimoxazole on the bone marrow
[39, 40].
TB has previously been associated with anaemia in HIV-infected patients [40]. In our study
patients TB was a common co-infection with HIV (41%). This prevalence is comparable to
previous reports on TB prevalence (43%) among severely anaemic HIV-infected patients in
Africa [9, 15]. The pathophysiology of TB-associated anaemia in HIV-infected patients
remains unclear. Bone marrow invasion by TB organisms or altered iron metabolism, as a side
effect of tuberculostatic drugs, have been described [41]. Only 13% of patients were on TB
treatment at enrolment. TB medication itself was not associated with the severity of anaemia
(OR 1.6 95%CI 0.7–3.8). Given that we and others have found TB in nearly half of the HIV-
infected patients with severe anaemia, TB screening and rapid initiation of treatment should
Fig 1. Total number of aetiologies for severe anaemia co-existing in each patient (n = 199). Mean is 3 factors (SD 1.3), range 1–8.
Aetiologies for severe anaemia include: 1) Unsuppressed HIV-infection; viral load�1000 copies/ml. 2) TB: one or more of the following were
present: a) positive sputum culture, b) chest X-ray with signs of pulmonary TB and/or c) on going TB treatment at time of enrolment d) clinical
diagnosis by local doctor including unknown generalized lymphadenopathy and/or night sweats of> 30 days and of unknown origin e)
caseating granulomata in the bone marrow trephine. 3) Malaria: presence of malaria parasites in a thick blood film. 4) Parvovirus B19: viral
load of>1000 copies/ml. 5) Cytomegalovirus (CMV); load of>100 copies/ml. 6) Epstein-Barr virus (EBV); viral load>100 copies/ml. 7)
Bacteraemia; a blood culture growing a potential pathogen. 8) Underweight (BMI�18.5). 9) Serum folate deficiency (�3 ng/l). 10) Vitamin
B12 deficiency (�180 pg/ml). 11). Iron deficiency defined by MCV� 83 fl. 12) Zidovudine usage. 13) Cotrimoxazole usage. 14) Bone marrow
disorders; lympho-proliferative disease, myeloid-proliferative disease or MDS. 15) Renal impairment: a GFR which either indicated impaired
(GFR 15–59 ml/min/1.73 m2) or End Stage (GFR�15 ml/min/1.73 m2) Renal Disease [22, 35].
https://doi.org/10.1371/journal.pone.0218695.g001
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be a high priority in the management of these patients, especially in resource limiting settings
where there is a high TB prevalence.
Viral infections such as EBV, CMV and parvovirus B19 have been associated with anaemia
in HIV-infected patients [42, 43]. In our study EBV and CMV were common and present in
40% and 35% of patients respectively, whilst parvovirus B19 was less common (4%). Although
parvovirus B19 is pathophysiologically linked to mild anaemia, its role in the development
severe anaemia in HIV infected patients has not been clearly established [43, 44]. Data on co-
infections are very limited in African patients [33, 45, 46]. Our study is the first to describe the
association between co-existing CMV and EBV infections and very severe anaemia (haemoglo-
bin�50 g/l] which may be related to direct viral inhibition of erythropoiesis [45, 47, 48]. The
majority of our patients with co-infection had advanced HIV disease (88.5%) but the associa-
tion between EBV and CMV co-infection and very severe anaemia remained significant even
after correction for advanced HIV disease. As CMV is a treatable infection it will be important
to determine the effect of ART on CMV infection and severe anaemia, as ART can reduce
CMV infection by improving immune status [49].
Malaria is unsurprisingly associated with anaemia in HIV-infected patients in sub-Saharan
Africa [2, 15]. However, the contribution of malaria to anaemia in our study population was
small as only 6 patients (3.5%) had malaria parasites on enrolment. This is in line with data
from other studies that show that the role of malaria in causing anaemia, especially in HIV
patients in sub-Saharan Africa [2, 14], is limited and likely to have been overestimated [31, 33].
Malnutrition was common in our population as half the patients had a BMI below 18.5m2
and deficiencies of iron and folate were diagnosed in 33.9% and 12% of the patients
Fig 2. Kaplan Meyer survival curve over time (days) for adult Malawian patients with HIV infection and severe anaemia during 365 days
follow-up. Abbreviation: 95% confidence interval (95% CI).
https://doi.org/10.1371/journal.pone.0218695.g002
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respectively. The prevalence of iron deficiency (MCV� 83 fl) in our study is higher than the
18%-25% prevalence reported in anaemic HIV-infected patients in sub-Saharan Africa
reported in previous studies [50, 51]. Interestingly, children and adults in sub-Saharan Africa
with severe anaemia but without HIV infection, have a higher prevalence of iron deficiency of
respectively 59% and 47%, than we found in our HIV-infected population [30,33]. Previous
studies on severe anaemic HIV patients were published before 2010; at that time ART avail-
ability was limited and all the studies included HIV-infected patients who were ART naïve and
who had high rates of immune suppression. HIV-infected patients who are in the early stages
of infection or who are on effective treatment may have better immune function so in these
patients the aetiology of severe anaemia (e.g. iron deficiency) may be more similar to that of
Fig 3. Risk factors for 365-day mortality in HIV-infected patients with severe anaemia. Univariate and multivariate Cox regression outcome
(Hazard Ratios 95% CI). Folate deficiency (�3 ng/l) HR 2.0 95% CI 1.2–3.6 and end stage renal disease (GFR�15); HR 3.0 5% CI 1.5–5.9, were
associated with overall mortality. Abbreviations: Hb: Haemoglobin, GFR; Glomerular filtration rate, VL Viral Load.
https://doi.org/10.1371/journal.pone.0218695.g003
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non-HIV infected patients [33]. Iron deficiency diagnosis is complicated by a lack of periph-
eral iron markers and microcytosis (i.e. low MCV) poorly reflects bone-marrow iron defi-
ciency especially in the context of HIV-infection (Huibers et al PLOS One, 2019). Bone
marrow evaluation remains the golden standard for diagnosis of iron deficiency. In addition
to finding a high prevalence of iron deficiency (MCV g 83 fl), ours is the first study to docu-
ment a possible association between folate deficiency and increased mortality in severely anae-
mic HIV-infected patients. There are a limited number of studies describing micronutrient
supplementation, including folate, for anaemic HIV-infected adults, but overall supplementa-
tion appears to have little effect on reducing morbidity and mortality [43,52]. Macronutrient
support using, for example, fortified wheat flour, has had beneficial effects on anaemia reduc-
tion and micronutrient levels in populations in sub-Saharan Africa, but has never been tested
in the context of severe anaemia in HIV-infected patients [53,54]. More research is therefore
needed to evaluate the effectiveness of both macro- and micro- nutritional support in severely
anaemic HIV-infected adults.
HIV-infected adults have an increased risk of neoplastic bone marrow diseases, which can
often cause anaemia [14]. However, prevalence data for such conditions among HIV-infected
patients with anaemia, especially in resource limiting settings, are scarce. Only three of our
study patients had confirmed bone marrow malignancies. In contrast, and in line with previ-
ous studies, MDS was common occurring in 27% of our patients [28,55].
Renal impairment was a frequent finding among our study patients and has been linked to
HIV disease progression, anaemia and poor outcomes in both wealthy and resource limited
settings [56–59]. Evaluation of renal function is an important component of severe anaemia
treatment protocols [34, 57] since it may affect the choice of ART [56, 60]. It may also have
implications for clinical management, for example by introducing measures to prevent further
deterioration or considering the use of erythropoietin[57].
Our study has several limitations. We purposely did not explore factors potentially associ-
ated with anaemia that previous studies had shown were uncommon in Malawi, such as hae-
moglobinopathies and parasitic infections [33, 61]. We also did not include an HIV-infected
population without severe anaemia against which to compare the prevalence of anaemia aetiol-
ogies and clinical outcomes. Only a sub-population of our patients gave consent for bone mar-
row sampling. Although these were an unselected group of patients it is possible that this may
have introduced a bias, for example by excluding the patients who were particularly unwell.
Nevertheless, our findings are very valuable since bone marrow data from HIV-infected Afri-
can patients is very scarce.
Conclusion
Our study has demonstrated that severe anaemia in HIV-infected adults in Malawi is associ-
ated with multiple co-existing aetiologies and has a strikingly high mortality rate. Severe anae-
mia in HIV-infected patients is therefore a critical indicator of mortality and requires urgent
and multiple interventions. Particularly important are the initiation of ART, the management
of infections such as TB and CMV, and optimisation of renal function. Intervention studies
are needed to properly define the role and safety of iron and folate supplementation, as well as
to develop and evaluate guidelines, which are feasible in resource-limited settings to help clini-
cians manage these patients more effectively.
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